M.AlamS.ShaoC.et al (2024)
Disclosures: Wen Zhang: Nothing to Disclose, Wenyue Wu: Nothing to Disclose, Ning Zhang: Nothing to Disclose, Hong Li: Nothing to Disclose, Yameng Sun: Nothing to Disclose, Xiaodong Ge: Nothing to Disclose, Hui Han: Nothing to Disclose, Shuyan Chen: Nothing to Disclose, Anjian Xu: Nothing to Disclose, Sai Santosh Babu Komakula: Nothing to Disclose, Chao Wang: Nothing to Disclose, Nithyananthan Subramaniyam: Nothing to Disclose, Qi Han: Nothing to Disclose, Xuzhen Yan: Nothing to Disclose, Aiting Yang: Nothing to Disclose, Natalia Nieto: Nothing to Disclose, Hong You: Nothing to Disclose, Wei Chen: Nothing to Disclose 2043 NOVEL BLOOD-BASED BIOMARKER MODEL FOR DIAGNOSIS OF HEPATIC FIBROSIS IN MASLD Eveline Gart Lars Verschuren 1 Anne Mak 2 Andre Boonstra 3 Joanne Verheij 4 Lise Lotte Gluud 5 Adriaan Holleboom 2 Maarten Tushuizen 6 , 1 TNO, 2 Amsterdam UMC, 3 Erasmus University Medical Center, 4 Academic Medical Center, 5 Copenhagen University - Hvidovre Hospital, 6 LUMC Background: Considering the escalating prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and related fibrosis, accurate non-invasive biomarkers for diagnosis and staging of fibrosis are urgently needed
Cell (2012) 149(6):126983.10.1016/j.cell.2012.04.026 67 FoulkesWDStefanssonIMChappuisPOBeginLRGoffinJRWongNet alGermline BRCA1 mutations and a basal epithelial phenotype in breast cancer
doi: 10.1093/mp/ssu049
doi: 10.1016/j.ejphar.2023.176264, 141
This antioxidant-based remedy is commonly administered in a sequence of injections over several months
